Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L, Jewell D, Powell P, Gillatt D, Dedman D, Mills N, Smith M, Noble S, Lane A

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
The overall aim was to evaluate the feasibility of a randomised controlled trial (RCT) of treatments for localised prostate cancer, including:

- feasibility of case-finding in the community (including the reliability and psychosocial impact of PSA testing)

- determining the most efficient and effective design for a major trial of treatments

- randomised trial of recruitment strategies

- piloting outcome measures and procedures for the main trial of treatments.

Authors' conclusions
It is feasible to mount a full-scale three-arm randomised trial of treatment for localised prostate cancer, preceded by a programme of case-finding in the UK.

The full-scale three-arm Prostate Testing for Cancer and Treatment (ProtecT) randomised trial of treatment has now been commissioned by the NHS R&D Health Technology Assessment Programme. It will be undertaken in nine clinical centres in the UK, involving over 100,000 men, and recruitment will take 5 years, commencing September 2001.

Project page URL
http://www.hta.ac.uk/1079

Indexing Status
Subject indexing assigned by CRD

MeSH
Mass Screening; Prostate-Specific Antigen; Prostatic Neoplasms /diagnosis

Language Published
English

Country of organisation
England

Address for correspondence
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk